Ms. Kari Odquist Kohl, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 21 Dupont Ave, White Plains, NY 10605 Phone: 914-686-0406 |
Elanor Schoomer, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 175 Tarrytown Rd, White Plains, NY 10607 Phone: 914-761-6566 Fax: 914-948-5533 |
Kathy Lynn Herron, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1241 Mamaroneck Ave, White Plains, NY 10605 Phone: 914-421-1500 Fax: 914-421-1501 |
Ms. Carol Ann Hughes, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 175 Tarrytown Rd, White Plains, NY 10607 Phone: 914-761-6566 |
Ms. Catherine Burger Keith, C.N.M Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 210 Westchester Ave, White Plains, NY 10604 Phone: 914-682-0732 Fax: 914-682-6403 |
Ms. Robin H Bradley, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1241 Mamaroneck Ave, White Plains, NY 10605 Phone: 914-421-1500 Fax: 914-421-1501 |
Lucille Catherine Milne, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 15 N Broadway, White Plains, NY 10601 Phone: 914-328-8444 Fax: 914-328-8414 |
News Archive
IRIDEX Corporation today announced the receipt of issuance of U.S. Patent No. 7,771,417, titled "Laser System with Short Pulse Characteristics And Its Method Of Use." This patent applies to the company's MicroPulseâ„¢ technology which provides the ophthalmologist with fine dose control of laser energy during eye surgery. Ophthalmologists are using MicroPulse technology to treat patients suffering from diabetic retinopathy and other sight-threatening retinal and glaucoma disorders.
An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world's most dangerous superbugs.
May Provide Therapeutic Target for Treating Inflammatory Bowel Disease and Preventing Colitis-Associated Colorectal Cancer, According to New Research Published in The American Journal of Pathology
GeoVax Labs, Inc., announced today the expansion of the Phase 2a clinical trial testing of its HIV/AIDS vaccine products. The expanded Phase 2a trial will test the administration of three doses of the recombinant poxvirus vaccine MVA62B without the use of the recombinant DNA-vectored vaccine, which was used to prime immune responses in the first part of this trial.
› Verified 9 days ago